Under gemcitabine treatment, a chemoresistant clone expressing EMT properties could be selected by inhibiting expression of the gemcitabine transporter ENT1 in pancreatic cancer cells via solute carrier family 39 member 4 (SLC39A4, also called ZIP4)-ZEB1 pathway [94]. This evidence concerns the gene SLC39A4 and pancreatic neoplasm.